| abstract |
A novel series of oxazole derivatives having enhanced water solubility bioavailability and metabolic stability is disclosed in the Formula I <IMAGE> FORMULA I wherein <IMAGE> <IMAGE> Y is CH3, Ph, or OH, provided that when Y is OH, the compound exists in the keto-enol tautaumerism form is H, OCH3, C1-C5 lower alkyl, or CO2R4; R4 is H or C1-C5 lower alkyl; R5 is H or CH3; R6 is OHCHN or H2N; and R7 is H or OH; or pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of ADP-induced blood platelet aggregation in human platelet-rich plasma. |